MBX Biosciences (MBX) Competitors $13.68 +1.98 (+16.92%) Closing price 07/23/2025 04:00 PM EasternExtended Trading$13.68 0.00 (0.00%) As of 07/23/2025 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock MBX vs. OCUL, APGE, IMCR, ADPT, SPRY, TARS, ETNB, JANX, SDGR, and EVOShould you be buying MBX Biosciences stock or one of its competitors? The main competitors of MBX Biosciences include Ocular Therapeutix (OCUL), Apogee Therapeutics (APGE), Immunocore (IMCR), Adaptive Biotechnologies (ADPT), ARS Pharmaceuticals (SPRY), Tarsus Pharmaceuticals (TARS), 89BIO (ETNB), Janux Therapeutics (JANX), Schrodinger (SDGR), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry. MBX Biosciences vs. Its Competitors Ocular Therapeutix Apogee Therapeutics Immunocore Adaptive Biotechnologies ARS Pharmaceuticals Tarsus Pharmaceuticals 89BIO Janux Therapeutics Schrodinger Evotec MBX Biosciences (NYSE:MBX) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership. Do insiders and institutionals believe in MBX or OCUL? 59.2% of Ocular Therapeutix shares are owned by institutional investors. 52.2% of MBX Biosciences shares are owned by company insiders. Comparatively, 2.3% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is MBX or OCUL more profitable? MBX Biosciences has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -323.09%. MBX Biosciences' return on equity of 0.00% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets MBX BiosciencesN/A N/A N/A Ocular Therapeutix -323.09%-59.92%-41.98% Do analysts rate MBX or OCUL? MBX Biosciences currently has a consensus target price of $37.57, indicating a potential upside of 174.64%. Ocular Therapeutix has a consensus target price of $17.33, indicating a potential upside of 44.93%. Given MBX Biosciences' higher possible upside, equities research analysts clearly believe MBX Biosciences is more favorable than Ocular Therapeutix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Ocular Therapeutix 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, MBX or OCUL? MBX Biosciences has higher earnings, but lower revenue than Ocular Therapeutix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMBX BiosciencesN/AN/AN/AN/AN/AOcular Therapeutix$63.72M29.90-$193.51M-$1.15-10.40 Does the media prefer MBX or OCUL? In the previous week, MBX Biosciences had 1 more articles in the media than Ocular Therapeutix. MarketBeat recorded 2 mentions for MBX Biosciences and 1 mentions for Ocular Therapeutix. MBX Biosciences' average media sentiment score of 0.34 beat Ocular Therapeutix's score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocular Therapeutix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryMBX Biosciences beats Ocular Therapeutix on 8 of the 10 factors compared between the two stocks. Get MBX Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBX vs. The Competition Export to ExcelMetricMBX BiosciencesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$457.24M$783.82M$5.57B$20.89BDividend YieldN/A4.84%4.05%3.62%P/E RatioN/A1.4028.1527.93Price / SalesN/A25.01401.6872.74Price / CashN/A19.5636.1922.61Price / BookN/A6.928.624.70Net IncomeN/A-$4.13M$3.24B$993.85M7 Day Performance12.22%2.37%3.55%1.99%1 Month Performance23.80%5.11%11.01%5.85%1 Year PerformanceN/A8.30%35.56%13.36% MBX Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBXMBX Biosciences2.2308 of 5 stars$13.68+16.9%$37.57+174.6%N/A$457.24MN/A0.0036High Trading VolumeOCULOcular Therapeutix3.6665 of 5 stars$11.06-1.9%$17.33+56.7%+48.6%$1.76B$63.72M-9.62230APGEApogee Therapeutics3.3549 of 5 stars$38.16-1.9%$99.00+159.5%-19.6%$1.76BN/A-10.6091Positive NewsIMCRImmunocore1.0609 of 5 stars$34.87-1.2%$58.89+68.9%-8.1%$1.75B$310.20M-81.09320ADPTAdaptive Biotechnologies3.002 of 5 stars$11.37-1.6%$10.57-7.0%+158.8%$1.72B$178.96M-11.82790SPRYARS Pharmaceuticals3.09 of 5 stars$17.51-2.2%$31.00+77.1%+74.4%$1.72B$97.12M-109.4090TARSTarsus Pharmaceuticals1.6792 of 5 stars$40.46-2.6%$66.67+64.8%+51.8%$1.70B$182.95M-14.8250ETNB89BIO1.8651 of 5 stars$10.63-4.4%$26.43+148.6%+15.3%$1.55BN/A-3.1440JANXJanux Therapeutics2.4026 of 5 stars$25.56-2.4%$91.89+259.6%-41.7%$1.51B$9.34M-18.7930SDGRSchrodinger2.1053 of 5 stars$20.59-2.6%$32.75+59.1%+1.6%$1.51B$207.54M-7.83790Upcoming EarningsEVOEvotec2.0989 of 5 stars$4.20+1.8%$5.93+41.4%-20.1%$1.49B$862.40M0.004,827 Related Companies and Tools Related Companies Ocular Therapeutix Competitors Apogee Therapeutics Competitors Immunocore Competitors Adaptive Biotechnologies Competitors ARS Pharmaceuticals Competitors Tarsus Pharmaceuticals Competitors 89BIO Competitors Janux Therapeutics Competitors Schrodinger Competitors Evotec Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MBX) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MBX Stock Alerts